UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 000-28508 98-1341933 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 10 Earlsfort Terrace Dublin 2, Ireland D02 ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jordan Dubow - Chief Medical Officer Conference Call Participants David Amsellem - Piper Sandler Paul Matthews - Stifel Francois Brisebois - Craig-Hallum Capital Group Matt Kaplan - Ladenburg Thalmann Operator Greetings, and welcome to the Avadel Pharmaceuticals’ First Quarter 2020 Financial Results Conference Call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Commission file number: 000-28508 AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) Ireland 98-1341933 State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) 10 Earlsfort Terrace Dublin 2, Ireland D02 T380 Not Applicable (Ad ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jordan Dubow - Chief Medical Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Paul Matthews - Stifel Francois Brisebois - Craig-Hallum Operator Greetings, and welcome to the Avadel Pharmaceuticals’ Fourth Quarter Year-End Financial Results Conference Call. At th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 000-28508 98-1341933 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Block 10-1, Blanchardstown Corporate Pa ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Michael Kanan - Chief Financial Officer Greg Divis - Chief Executive Officer Jordan Dubow - Chief Medical Officer Conference Call Participants Operator Greetings. Welcome to Avadel Third Quarter 2019 Earnings Call. At this time, all participants are in a listen-only mode. [Operators Instructions] Please note this conference is being recorded. I will now turn the conference over to your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 000-28508 98-1341933 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Block 10-1, Blanchardstown Corporate Park Ba ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2019 Earnings Conference Call August 9, 2019 8:30 AM ET Company Participants Mike Kanan - Chief Financial Officer Greg Divis - Chief Executive Officer Jordan Dubow - Chief Medical Officer Conference Call Participants François Brisebois - Laidlaw Yinglu Zhang - Ladenburg Thalmann Michael Sesser - DWS Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Avadel Pharmaceuticals Second Quarter 2019 Financial Results Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 000-28508 98-1341933 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Block 10-1, Blanchardstown Corporate Park B ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Greg Divis - Interim CEO Mike Kanan - CFO Jordon Dubow - CMO Geoff Glass - Chairman Conference Call Participants Operator Good morning, ladies and gentlemen, thank you for standing by. And welcome to the Avadel Pharmaceuticals’ First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session a ...